FDA Sides With Panel In Downclassifying Antimicrobial Susceptibility Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA will likely not require additional post-market surveillance from companies manufacturing automated short-term incubation cycle (STIC) antimicrobial susceptibility devices (ASDs), the agency says in the March 8 Federal Register.